68ga-dota-jr11
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 13, 2015 (NCT02609737)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Also known as
- 68ga-dota-jr11
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04897542 | Early Phase 1 (Phase 1) | Dec 1, 2020 | Fujian Medical University |
| NCT04689893 | Phase 1 | Mar 15, 2020 | Chinese Academy of Medical Sciences |
| NCT02609737 | N/A | Nov 13, 2015 | Cornell University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1